Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P4HB | P07237 | 1/20 | 0.67 |
| ▸ | PDIA4 | P13667 | 1/20 | 0.67 |
| ▸ | PDIA3 | P30101 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA4 | P22748 | 2/20 | 0.53 |
| ▸ | CA5A | P35218 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14106783 | 1.00 | P4HB (0.67) | P4HBPDIA4PDIA3TSHRCA12 | |
| SCHEMBL14106804 | 1.00 | P4HB (0.67) | P4HBPDIA4PDIA3TSHRCA12 | |
| SCHEMBL14106785 | 0.96 | P4HB (0.65) | P4HBPDIA4PDIA3TSHRCA12 | |
| SCHEMBL13402798 | 0.96 | P4HB (0.65) | P4HBPDIA4PDIA3TSHRCA12 | |
| SCHEMBL3961735 | 0.82 | P4HB (0.62) | P4HBPDIA4PDIA3TSHRCA12 | |
| SCHEMBL3957917 | 0.82 | P4HB (0.62) | P4HBPDIA4PDIA3TSHRCA12 | |
| SCHEMBL13402799 | 0.82 | P4HB (0.60) | P4HBPDIA4PDIA3TSHRCYP2D6 | |
| SCHEMBL24598883 | 0.82 | TSHR (0.67) | P4HBPDIA4PDIA3TSHRCYP2D6 | |
| SCHEMBL4609383 | 0.82 | TSHR (0.67) | P4HBPDIA4PDIA3TSHRCYP2D6 | |
| SCHEMBL7694818 | 0.82 | TSHR (0.67) | P4HBPDIA4PDIA3TSHRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546421-B1 | Oncogenic-RAS-signal dependent lethal compounds | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-10-01 | — | — | US | disclosed |
| US-8546421-B1 | Oncogenic-RAS-signal dependent lethal compounds | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2013-10-01 | — | — | US | disclosed |
| US-20100081654-A1 | Oncogenic-RAS-signal dependent lethal compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
| US-20100081654-A1 | Oncogenic-RAS-signal dependent lethal compounds | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081654-A1 | Oncogenic-RAS-signal dependent lethal compounds | HRAS, KRAS, NRAS | P4HB 4310/4885PDIA4 3567/4885PDIA3 3793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.